Ensign Group raises FY25 EPS view to $6.48-$6.54 from $6.34-$6.46

Consensus $6.41. Raises FY25 revenue view to $5.05B-$5.07B from $4.99B-$5.02B, consensus $5.01B. “After another stronger than expected quarter, we are raising our annual 2025 earnings guidance to between $6.48 to $6.54 per diluted share, up from $6.34 to $6.46 per diluted share. The new midpoint of this increased 2025 earnings guidance represents an increase of 18.4% over our 2024 results and is 36.5% higher than our 2023 results. We are also increasing our annual revenue guidance to $5.05 billion to $5.07 billion, up from $4.99 billion to $5.02 billion, to account for our current quarter growth and acquisitions we have closed and anticipate closing through the remainder of the year. We are very proud of the results our local operators have achieved so far in 2025 and are confident that our partners will continue to manage and innovate while balancing the addition of newly acquired operations. We are excited about the trajectory we are on for the year and look forward to continuing our consistent march towards great clinical and financial results,” Port said.